Janssen (United Kingdom)

Evaluating the Impact of Outcome Delay on the Efficiency of Sample Size Re‐Estimation

ABSTRACT Sample size re‐estimation (SSR) can be a powerful tool to ensure that a clinical trial meets its pre‐specified power requirements when uncertainty regarding a design parameter exists at the planning stage. However, long‐term primary endpoints can be harmful to the effici...